Table 2.

Pre-chemotherapy cardiovascular evaluation (N=92).

Type of chemotherapy	N (%)
Anthracycline based regimens	48 (52%)
Non-anthracycline based regimens	44 (48%)
HER2 targeted therapies*	12 (27%)
Tyrosine kinase inhibitors°	11 (25%)
Other therapies (including non-HER2 monoclonal antibodies)#	21 (48%)

*Includes: trastuzumab; pertuzumab

°Includes: axitinib; bosutinib; dabrafenib; imatinib; nilotinib; pona-tinib; sunitinib; tremetinib

#Includes: 5-fluorouracil; abiraterone; bortezomib; carfilzomib; cituximab; fludarabine; gemcitabine; lenalidomide; melphalan; nitrogen mustard; paclitaxel; platinum compounds (carboplatin; cisplatin; oxaliplatin); vincristine.